Richard Reinisch Net Worth

The estimated Net Worth of Richard Reinisch is at least $6.84 Milione dollars as of 12 March 2010. Richard Reinisch owns over 1,100,000 units of La Jolla Pharmaceutical Co stock worth over $6,842,000 and over the last 15 years Richard sold LJPC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Reinisch LJPC stock SEC Form 4 insiders trading

Richard has made over 1 trades of the La Jolla Pharmaceutical Co stock since 2010, according to the Form 4 filled with the SEC. Most recently Richard bought 1,100,000 units of LJPC stock worth $121,000 on 12 March 2010.

The largest trade Richard's ever made was buying 1,100,000 units of La Jolla Pharmaceutical Co stock on 12 March 2010 worth over $121,000. On average, Richard trades about 1,100,000 units every 0 days since 2010. As of 12 March 2010 Richard still owns at least 1,100,000 units of La Jolla Pharmaceutical Co stock.

You can see the complete history of Richard Reinisch stock trades at the bottom of the page.

What's Richard Reinisch's mailing address?

Richard's mailing address filed with the SEC is 4 BARRETT WOODS, , BALLWIN, MO, 63021.

Insiders trading at La Jolla Pharmaceutical Co

Over the last 21 years, insiders at La Jolla Pharmaceutical Co have traded over $13,460,170 worth of La Jolla Pharmaceutical Co stock and bought 11,640,515 units worth $137,250,039 . The most active insiders traders include Advisors Llcperceptive Life..., James N Topper e Woodlands Health Ventures F.... On average, La Jolla Pharmaceutical Co executives and independent directors trade stock every 63 days with the average trade being worth of $1,249,971. The most recent stock trade was executed by Craig A Johnson on 8 July 2022, trading 12,000 units of LJPC stock currently worth $47,160.

What does La Jolla Pharmaceutical Co do?

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria.

Complete history of Richard Reinisch stock trades at La Jolla Pharmaceutical Co

La Jolla Pharmaceutical Co executives and stock owners

La Jolla Pharmaceutical Co executives and other stock owners filed with the SEC include:

• Larry G. Edwards,
  Pres, CEO & Director
• Dr. Lakhmir S. Chawla,
  Consultant
• Michael S. Hearne,
  CFO & Sec.
• David Ramsay,
  Independent Director
• Craig Johnson,
  Independent Director
• Robert Rosen,
  Independent Director
• Laura Douglass,
  Independent Director
• Kevin Tang,
  Chairman of the Board
• Michael Hearne,
  Chief Financial Officer, principal financial officer, Principal Accounting Officer
• Larry Edwards,
  President, Chief Executive Officer, Director
• Tony N. Hodges FACP, M.D.,
  Chief Medical Officer
• Mark D. Williams,
  Sr. VP of Medical Affairs
• Stewart M. Kroll,
  Chief Devel. Officer
• Luke Seikkula,
  Sr. VP of Pharmaceutical Operations
• Thomas Ouellette,
  VP of Sales & Marketing
• Sandra Vedrick,
  Sr. Director of Investor Relations & HR
• Paula Rusu,
  VP of Operations
• Darryl Wellinghoff,
  Chief Commercial Officer
• Dennis Mulroy,
  Chief Financial Officer
• George F Tidmarsh,
  President and CEO
• Laura L. Johnson,
  Director
• James Rolke,
  Chief Scientific Officer
• Lakhmir S Chawla,
  Chief Medical Officer
• Kevin Ctang Capital Partner...,
  
• Jennifer Carver,
  Chief Operating Officer
• Advisors Llcperceptive Life...,
  
• Steven B Engle,
  CEO & Chairman
• Deirdre Gillespie,
  CEO
• Richard Reinisch,
  
• Gail A Sloan,
  Sen Dir of Finance/Controller
• Paul Jenn,
  VP of Product Development
• W Leigh Md Phd Thompson,
  Director
• Lisa I Koch,
  Sr Dir Regulatory Affairs
• Saiid Zarrabian,
  Director
• Matthew D Linnik,
  CSO & Exec VP of Research
• Bruce K Jr Bennett,
  VP of Manufacturing
• Teddi Reilly,
  VP of Human Resources
• Andrew Wiseman,
  Sen Dir Business Development
• William J Welch,
  VP Sales & Marketing
• Luke Seikkula,
  Vice President Manufacturing
• William R Ringo,
  Director
• Kenneth R Heilbrunn,
  VP of Clinical Development
• Robert Phd Fildes,
  Director
• Craig R Smith,
  Director
• William Engbers,
  Director
• Josefina T Elchico,
  Vice President Quality System
• Alejandro Gonzalez,
  10% owner
• Michael James Byron Tansey,
  Chief Medical Officer
• Healthcare V, Lp Frazier,
  10% owner
• Thomas Phd Adams,
  Director
• James N Topper,
  Director
• Healthcare V, Lpfhm V, Llcf...,
  
• Stephen Martin,
  Director
• Bertrand C. Liang,
  Director
• Woodlands Health Ventures F...,
  10% owner
• Nader J Naini,
  Director
• Niv Edward Caviar,
  Chief Business Officer & CFO
• Martin P Sutter,
  Director
• Woodlands Health Ventures F...,
  10% owner
• Pharmaceutical Inc Biomarin,
  10% owner
• Frank Young,
  Director
• Kevin Ctang Capital Partner...,
  Chief Financial Officer